#ai-in-drug-discovery

#ai-in-drug-discovery

Eli Lilly's stock has experienced significant growth, indicating strong market confidence and potential for future stock splits.

Investors should focus on projected revenue and innovations rather than solely on past performance when evaluating Eli Lilly's future. [ more ]

AI can speed up the process of designing, finding, and testing new drugs

90% of clinical drug development fails, leading to wasted costs of over $2 billion per project [ more ]

Boehringer Ingelheim is collaborating with IBM to use AI in the search for new treatments and therapies.

The partnership aims to use a pre-trained AI model and proprietary data to accelerate the discovery of potential antibodies. [ more ]